SecSonar.com

Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Theravance Biopharma, Inc. (TBPH) is a Biotechnology company based in KY with a market capitalization of $835.7M. Revenue grew 66.9% year-over-year and the company generated $238.5M in free cash flow. This page tracks TBPH's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

KY · 97 employees · IPO May 16, 2014

Valuation

Valuation & price

$16.22 · as of May 17, 2026 · -21.8% vs 52w high

7.9

P/E ratio

Latest-FY diluted EPS

2.82

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$20.61$15.82$11.03Jul 25Dec 25Jun 26Jul 7, 25$11.31Jul 9, 25$11.59Jul 11, 25$11.30Jul 15, 25$11.53Jul 17, 25$11.62Jul 21, 25$11.35Jul 23, 25$11.30Jul 25, 25$11.03Jul 29, 25$11.03Jul 31, 25$11.16Aug 4, 25$11.22Aug 6, 25$11.18Aug 8, 25$11.52Aug 12, 25$11.92Aug 14, 25$12.94Aug 18, 25$13.61Aug 20, 25$13.39Aug 22, 25$13.91Aug 27, 25$13.80Aug 29, 25$13.88Sep 3, 25$13.74Sep 5, 25$13.95Sep 9, 25$13.76Sep 11, 25$13.70Sep 15, 25$14.40Sep 17, 25$14.05Sep 19, 25$13.88Sep 23, 25$14.07Sep 25, 25$13.79Sep 29, 25$14.43Oct 1, 25$14.42Oct 3, 25$14.41Oct 7, 25$14.35Oct 9, 25$14.51Oct 13, 25$13.92Oct 16, 25$14.04Oct 20, 25$14.31Oct 22, 25$14.00Oct 24, 25$14.28Oct 28, 25$14.10Oct 30, 25$14.30Nov 3, 25$15.22Nov 5, 25$14.95Nov 7, 25$14.75Nov 11, 25$18.50Nov 13, 25$17.95Nov 17, 25$18.04Nov 19, 25$17.73Nov 21, 25$18.48Nov 25, 25$18.94Nov 28, 25$20.30Dec 2, 25$18.43Dec 5, 25$18.55Dec 9, 25$17.81Dec 11, 25$17.68Dec 15, 25$17.77Dec 17, 25$17.91Dec 19, 25$18.79Dec 23, 25$18.57Dec 26, 25$18.84Dec 30, 25$18.91Jan 2, 26$18.15Jan 6, 26$18.30Jan 8, 26$19.02Jan 12, 26$19.65Jan 14, 26$20.61Jan 16, 26$20.01Jan 21, 26$20.37Jan 23, 26$20.24Jan 28, 26$19.03Jan 30, 26$18.94Feb 3, 26$19.99Feb 5, 26$19.58Feb 9, 26$19.50Feb 11, 26$19.51Feb 13, 26$19.53Feb 18, 26$19.17Feb 20, 26$19.66Feb 24, 26$19.06Feb 26, 26$18.19Mar 2, 26$18.95Mar 4, 26$13.67Mar 6, 26$13.57Mar 10, 26$14.03Mar 12, 26$13.89Mar 16, 26$13.93Mar 19, 26$14.01Mar 23, 26$14.75Mar 25, 26$15.29Mar 27, 26$15.08Mar 31, 26$16.23Apr 2, 26$16.02Apr 7, 26$16.56Apr 9, 26$16.55Apr 13, 26$16.50Apr 15, 26$16.64Apr 17, 26$17.23Apr 21, 26$16.62Apr 23, 26$16.31Apr 27, 26$16.81Apr 29, 26$16.67May 1, 26$16.79May 5, 26$16.73May 8, 26$17.01May 12, 26$16.48May 14, 26$16.51May 18, 26$16.26May 20, 26$16.55May 22, 26$16.37May 27, 26$16.26May 29, 26$16.06Jun 2, 26$15.58Jun 4, 26$16.37Jun 8, 26$16.29Jun 10, 26$16.37Jun 12, 26$16.64Jun 16, 26$16.69Jun 18, 26$16.58Jun 23, 26$16.97Jun 29, 26$17.06
$10.9052-week range$20.74
Loading valuation history…

Fundamentals

Key fundamentals

$835.7M

Market cap

66.9%

Revenue growth (YoY)

94.9%

Gross margin

$238.5M

Free cash flow (USD)

-$239.9M

Net debt

Net cash position

3.0%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$48.6MFY 2017$15.4MFY 2018$60.4MFY 2019$73.4MFY 2020$71.9MFY 2021$55.3MFY 2022$51.3MFY 2023$57.4MFY 2024$64.4MFY 2025$107.5M
$48.6M$107.5M

Free cash flow by year

2016 → 2025

FY 2016$-101.1MFY 2017$-203.5MFY 2018$-120.1MFY 2019$-241.4MFY 2020$-257.0MFY 2021$-211.3MFY 2022$-187.6MFY 2023$-29.5MFY 2024$-11.9MFY 2025$238.5M
-$101.1M$238.5M

Gross margin by year

2021 → 2025

FY 2021-250.1%FY 2022-23.5%FY 202329.3%FY 2024100.0%FY 202594.9%
-250.1%94.9%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

2

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $5.8MSamaha Eli · 10% Owner · $5.8MJul 1, 2026Filing
  • 8-K eventMerger AgreementJun 29, 2026Filing
  • 8-K eventExecutive DepartureJun 23, 2026Filing
  • Insider sellInsider Sell $218KFarnum Rhonda · SVP, COMM & MEDICAL AFFAIRS · $218.2KJun 17, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 12, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing

Questions

Frequently asked questions

What is Theravance Biopharma, Inc.'s market cap?

Theravance Biopharma, Inc. (TBPH) has a market capitalization of $835.7M.

What is TBPH's P/E ratio?

TBPH trades at a price-to-earnings ratio of 7.9, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is TBPH's price-to-book (P/B) ratio?

TBPH trades at 2.82 times book value per share.

Are insiders buying TBPH stock?

SEC Form 4 filings show no open-market insider buys at Theravance Biopharma, Inc. in the last 90 days (2 sells).

Same arena

Related companies in Biotechnology

ETON

Eton Pharmaceuticals, Inc.

$834.6M

ZBIO

Zenas BioPharma, Inc.

$829.2M

GERN

Geron Corporation

$805.1M

PHAT

Phathom Pharmaceuticals, Inc.

$788.3M

XNCR

Xencor, Inc.

$885.3M

JANX

Janux Therapeutics, Inc.

$894.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.